Short-term treatment (6 weeks) with 10 mg prednisolone effectively reduces finger pain and improves function in patients who have painful hand osteoarthritis (OA) coupled with signs of inflammation, the HOPE* study has shown.
The coronavirus has been spreading at a frantic pace, isolating families and snuffing out lives. As hunger and emotional contagion grip the nations, the hope of a containment also dims. No one has seen this enemy coming – the world has underestimated COVID-19.
Dr Poon Shi Hui, a consultant at the Department of Psychiatry at Singapore General Hospital, speaks to Roshini Claire Anthony on the different types of insomnia and the various management strategies deployed for each type.
A long-acting (LA) injectable therapeutic regimen comprising the integrase strand-transfer inhibitor cabotegravir and the nonnucleoside reverse-transcriptase inhibitor rilpivirine maintained viral suppression among virologically suppressed adults with HIV-1, according to the week 96 results of the phase III FLAIR* trial.
Perineal interferential current (IC) proves beneficial in the treatment of women with premature ovarian insufficiency (POI) who are using systemic hormone therapy (HT) and presenting with sexual complaints, with the results of a 4-week trial showing that IC yields favourable effects on pain, lubrication, satisfaction and orgasm as compared with topical estriol.
Adding cilostazol to other antiplatelet agents could potentially reduce in-stent restenosis (ISR) among patients with carotid artery stenosis who undergo carotid artery stenting (CAS), according to results of the CAS-CARE* trial presented at ISC 2020.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
A recent genome-wide association study (GWAS) performed by investigators from the Chinese University of Hong Kong (CUHK) has found potential new indications for existing drugs for the treatment of various psychiatric disorders.
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.